US · ALGS
Aligos Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- South San Francisco, CA 94080
- Website
- aligos.com
Price · as of 2024-12-31
$6.09
Market cap 43.26M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $5.18 | -14.94% |
| Intrinsic Value(DCF) | $5.18 | -14.94% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $1,324.26 | +21,644.78% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $653.50 | ||||
| 2021 | $64.75 | ||||
| 2022 | $33.00 | $54.49 | $0.00 | $0.00 | $0.00 |
| 2023 | $21.00 | $25.88 | $0.00 | $0.00 | $0.00 |
| 2024 | $12.94 | $5.18 | $0.00 | $0.00 | $1,324.26 |
AI valuation
Our deep-learning model estimates Aligos Therapeutics, Inc.'s (ALGS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $5.18
- Current price
- $6.09
- AI upside
- -14.94%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$5.18
-14.94% upside
Graham-Dodd
—
— upside
Graham Formula
$1,324.26
+21,644.78% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ALGS | Aligos Therapeutics, Inc. | $6.09 | 43.26M | -15% | -15% | — | +21,645% | -0.62 | -2.80 | 20.55 | -0.38 | -0.12 | -2.80 | 100.00% | -2259.92% | -3326.01% | -415.84% | 162.06% | -118.41% | -0.29 | — | 2.86 | 2.62 | 0.33 | 49489.00% | -7460.00% | 235.00% | -99.76% | -3.71 | 147.01% | 0.00% | 0.00% | 0.00% | -0.36 | -0.40 | 8.24 | -15.30 |
| BRNS | Barinthus Biotherapeutics… | $0.58 | 23.85M | +43,665% | +73% | — | — | -0.63 | 0.30 | 2.59 | 1.08 | — | 0.36 | 100.00% | -454.07% | -408.00% | -38.62% | -152.56% | -32.65% | 0.09 | -1282.45 | 8.03 | 7.90 | 1.78 | -1885.00% | 176646.00% | -4705.00% | -76.97% | -1.85 | -67.01% | 0.00% | 0.00% | 0.00% | 0.88 | 2.01 | -4.00 | -1.79 |
| FGEN | FibroGen, Inc. | $9.07 | 36.69M | +230% | -59% | — | +42% | -19.49 | -4.11 | 31.31 | -6.67 | — | -4.11 | 47.47% | -507.80% | -160.63% | 22.14% | 63.58% | -14.91% | -0.32 | -18.24 | 1.47 | 0.60 | -0.16 | -8356.00% | -3671.00% | -5646.00% | -14.91% | -1.04 | 58.55% | 0.24% | -4.70% | 3.92% | -6.32 | -6.87 | 32.07 | -12.76 |
| INMB | INmune Bio, Inc. | $1.29 | 34.29M | +2,143% | +149% | — | +12,808% | -3.80 | 4.98 | 11425.06 | -3.31 | -14.43 | 10.26 | 100.00% | -304535.71% | -300585.71% | -119.83% | -351.09% | -87.16% | 0.01 | — | 3.14 | 3.09 | 0.49 | 2635.00% | -9097.00% | 17847.00% | -20.86% | -4.62 | -274.72% | 0.00% | 0.00% | 0.00% | -3.27 | -4.18 | 9958.06 | 4.00 |
| KZR | Kezar Life Sciences, Inc. | $6.70 | 49.07M | +394% | — | — | — | -5.31 | 3.80 | — | -4.05 | — | 3.80 | 0.00% | — | — | -55.00% | -3029.25% | -45.77% | 0.14 | -56.88 | 6.76 | 6.53 | 0.32 | -1786.00% | -10000.00% | -1104.00% | -16.69% | -3.65 | -2482.15% | 0.00% | 0.00% | 2.03% | -3.63 | -4.43 | — | 4.31 |
| MRSN | Mersana Therapeutics, Inc… | $29.08 | 145.36M | +85% | +9,159% | — | — | -0.96 | -7.01 | 1.65 | 0.62 | — | -7.01 | 95.98% | -181.09% | -170.86% | -505.14% | 57.77% | -37.33% | -3.01 | -18.93 | 2.19 | 2.16 | 1.25 | -6180.00% | 988.00% | -5178.00% | -123.65% | -1.32 | 64.97% | 0.00% | 0.00% | 0.00% | 0.54 | 0.48 | -0.97 | -9.18 |
| OKUR | OnKure Therapeutics, Inc. | $2.71 | 36.72M | — | — | — | — | -1.27 | 0.64 | — | 0.83 | -2.59 | 0.64 | 0.00% | — | — | -5304.43% | 79.46% | -69.93% | 0.01 | -181.29 | 10.73 | 10.52 | 2.12 | 4906.00% | — | 4707.00% | -76.41% | -4.85 | 74.76% | 0.00% | 0.00% | 120.18% | 0.79 | 0.83 | — | 1.25 |
| SKYE | Skye Bioscience, Inc. | $0.74 | 23.88M | — | — | — | — | -3.61 | 1.41 | — | -1.11 | — | 1.41 | 0.00% | — | — | -80.48% | -4256.79% | -62.73% | 0.01 | -31.20 | 16.32 | 15.77 | 2.69 | -8641.00% | — | 9221.00% | -27.97% | -5.82 | -3784.31% | 0.00% | 0.00% | 74.32% | -0.93 | -1.04 | — | 9.69 |
| TPST | Tempest Therapeutics, Inc… | $2.28 | 11.23M | — | — | — | — | -7.25 | 15.85 | — | -7.18 | — | 15.85 | 0.00% | — | — | -182.35% | -676.64% | -89.90% | 0.80 | -31.93 | 2.21 | 2.13 | 0.37 | -2147.00% | — | 2156.00% | -11.03% | -2.32 | -538.75% | 0.00% | 0.00% | 0.00% | -6.86 | -8.62 | — | -1.70 |
| XFOR | X4 Pharmaceuticals, Inc. | $3.44 | 39.24M | — | +23% | — | — | -1.89 | 3.20 | 27.68 | -1.70 | — | -13.60 | 68.83% | -1423.58% | -1464.61% | -102.26% | 1092.96% | -25.50% | 3.53 | -4.15 | 3.41 | 3.16 | -0.81 | -6731.00% | — | 3589.00% | -185.42% | -3.98 | 3940.16% | 0.00% | 0.00% | 0.00% | -1.29 | -0.36 | 18.30 | -4.74 |
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
- CEO
- Lawrence Blatt
- Employees
- 70
- Beta
- 2.66
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($5.18 ÷ $6.09) − 1 = -14.94% (DCF, example).